A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Seminars in nuclear medicine Pub Date : 2023-11-18 DOI:10.1053/j.semnuclmed.2023.11.001

Andrew F. Voter MD, PhD , Rudolf A. Werner MD , Hatice Savas MD , Andrei Gafita MD , Ashley E. Ross MD, PhD , Michael A. Gorin MD , Lilja B. Solnes MD, MBA , Martin G. Pomper MD, PhD , Steven P. Rowe MD, PhD , Sara Sheikhbahaei MD, PhD

{"title":"A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging","authors":"Andrew F. Voter MD, PhD , Rudolf A. Werner MD , Hatice Savas MD , Andrei Gafita MD , Ashley E. Ross MD, PhD , Michael A. Gorin MD , Lilja B. Solnes MD, MBA , Martin G. Pomper MD, PhD , Steven P. Rowe MD, PhD , Sara Sheikhbahaei MD, PhD","doi":"10.1053/j.semnuclmed.2023.11.001","DOIUrl":null,"url":null,"abstract":"<div><p><span>Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer<span>, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies. This has led to a rapid expansion in both the number of PSMA PET scans performed and the imaging specialists required to interpret those scans. To aid those imagers and clinicians who are new to the interpretation of PSMA PET, this review provides an overview of the interpretation of PSMA PET/CT imaging and pearls for overcoming commonly encountered pitfalls. We discuss the physiologic distribution of the clinically available PSMA-targeted </span></span>radiotracers, the commonly encountered patterns of prostate cancer spread, as well as the benign and malignant mimics of prostate cancer. Additionally, we review the standardized PSMA PET reporting systems and the role of PSMA in selecting appropriate patients for PSMA-targeted therapies.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299823000880","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies. This has led to a rapid expansion in both the number of PSMA PET scans performed and the imaging specialists required to interpret those scans. To aid those imagers and clinicians who are new to the interpretation of PSMA PET, this review provides an overview of the interpretation of PSMA PET/CT imaging and pearls for overcoming commonly encountered pitfalls. We discuss the physiologic distribution of the clinically available PSMA-targeted radiotracers, the commonly encountered patterns of prostate cancer spread, as well as the benign and malignant mimics of prostate cancer. Additionally, we review the standardized PSMA PET reporting systems and the role of PSMA in selecting appropriate patients for PSMA-targeted therapies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PSMA PET成像的优点和缺陷的实用指南。

前列腺特异性膜抗原(PSMA)靶向PET药物已经彻底改变了前列腺癌患者的护理，取代了传统的前列腺癌成像方法，并改善了治疗方法的选择和提供。这导致了PSMA PET扫描的数量和解释这些扫描结果所需的成像专家的迅速增加。为了帮助那些不熟悉PSMA PET解释的成像人员和临床医生，本综述概述了PSMA PET/CT成像的解释以及克服常见陷阱的建议。我们讨论了临床可用的psma靶向放射性示踪剂的生理分布，前列腺癌扩散的常见模式，以及前列腺癌的良性和恶性模拟。此外，我们回顾了标准化的PSMA PET报告系统和PSMA在选择合适的PSMA靶向治疗患者中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.

期刊最新文献

Letter From the Editors. Clinical Explorations of [⁶⁸Ga] Ga-FAPI-04 and [¹⁸F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging. Emerging TSPO-PET Radiotracers for Imaging Neuroinflammation: A Critical Analysis. Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies. Update on PSMA-based Prostate Cancer Imaging.